Over the past two years, the United States Supreme Court has had two opportunities to address and add to the jurisprudence in the area of federal pre-emption of state law claims regarding allegedly defective medical devices and prescription drugs, which are both regulated by the US Food and Drug Administration (FDA). In Riegel v. Medtronic, Inc., 128 S.Ct. 999 (U.S. 2008), the United States Supreme Court held that the Medical Device Act's pre-emption clause expressly pre-empts state law claims challenging the safety and effectiveness of a medical device marketed in a form that received premarket approval from the FDA. The Court made it explicitly clear, however, that such claims are only pre-empted insofar as they seek to impose state requirements that are "different from, or in addition to" the requirements imposed by federal law. Id. at 1011.
Please see full article below for more information.
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.